Description
Brazil
Canada - Français
Deutschland
France
Ελλάδα
Ireland
Latin America
Netherlands
Spain
United Kingdom
United States
日本
Other Countries
Prof. Stephen Chia (Canada) and Dr. Mark Verrill (UK) discuss the initial RxPONDER results presented at SABCS 2020 and what impact this has on the clinical practice.
8 December 2021 New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making
1 December 2021 Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
20 May 2021 New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer
24 March 2021 New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer
9 December 2020 RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
2 October 2020 New Real-World Evidence Further Demonstrates the Clinical Utility of the Oncotype DX Breast Recurrence Score® Test, Beyond Clinical Risk Factors, in Guiding Chemotherapy Treatment Decisions in Patients with Early-stage Breast Cancer
29 May 2020 New Data and Society Guidelines Support Value of Oncotype DX Breast Recurrence Score® Test in Guiding Neoadjuvant Treatment Decisions for Newly Diagnosed Patients
14 May 2020 New Oncotype DX Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
12 December 2019 New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer
30 September 2019 New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment
21 August 2019 New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy for Node-Negative and Node-Positive Early-Stage Breast Cancer
21 June 2019 German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test
4 June 2019 Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
3 June 2019 Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score Test in Node-negative Breast Cancer
25 March 2019 New Long-Term Outcomes Data Reconfirm Value of Oncotype DX Breast Recurrence Score Test to Target Chemotherapy